CARIBOU BIOSCIENCES
Caribou Biosciences is a operator of a medical technology company intended to analyze cell and genome engineering. The company specializes in cellular engineering and analysis based on the CRISPR-Cas9 technology platform which paired with a guide RNA, cuts double-stranded DNA and allows for specific changes to DNA, enabling development of therapeutics for agricultural biotechnology, industrial biotechnology and basic and applied biological research.
CARIBOU BIOSCIENCES
Industry:
Biotechnology Health Care Therapeutics
Founded:
2011-01-01
Address:
Berkeley, California, United States
Country:
United States
Website Url:
http://www.cariboubio.com
Total Employee:
101+
Status:
Active
Contact:
510-982-6030
Email Addresses:
[email protected]
Total Funding:
167.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Font Awesome Domain Not Resolving Apache
Similar Organizations
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Ikena Oncology
Ikena Oncology is a biotechnology company that advances new immunometabolic therapies for cancer.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
LifeSci Venture Partners
LifeSci Venture Partners investment in Series C - Caribou Biosciences
Avego Bioscience Capital
Avego Bioscience Capital investment in Series C - Caribou Biosciences
Maverick Ventures
Maverick Ventures investment in Series C - Caribou Biosciences
Ridgeback Capital
Ridgeback Capital investment in Series C - Caribou Biosciences
Farallon Capital Management
Farallon Capital Management investment in Series C - Caribou Biosciences
Avidity Partners
Avidity Partners investment in Series C - Caribou Biosciences
Janus Henderson Investors
Janus Henderson Investors investment in Series C - Caribou Biosciences
Adage Capital Management
Adage Capital Management investment in Series C - Caribou Biosciences
AbbVie Biotech Ventures
AbbVie Biotech Ventures investment in Series C - Caribou Biosciences
Heritage Group
Heritage Group investment in Series C - Caribou Biosciences
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2014-11-18 | Intellia Therapeutics | Caribou Biosciences investment in Series A - Intellia Therapeutics | 15 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2020-05-15 | Cherry Thomas joins Caribou as SVP of clinical development; Artax locks in Joseph Lobacki as CEO |
Official Site Inspections
http://www.cariboubio.com Semrush global rank: 3.31 M Semrush visits lastest month: 4.88 K
- Host name: ec2-34-192-255-123.compute-1.amazonaws.com
- IP address: 34.192.255.123
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Caribou Biosciences"
Caribou Biosciences | Developing Sophisticated …
Armored for enhanced activity. We believe armoring is the key to unlocking the full potential of allogeneic cell therapies. We use our chRDNA technologies to armor our cell therapies through multiple genome-editing strategies, including …See details»
Caribou Biosciences - Crunchbase Company Profile
Caribou Biosciences is an operator of a medical technology company intended to analyze cell and genome engineering. The company specializes in cellular …See details»
Committee composition - Caribou Biosciences, Inc.
Caribou Biosciences, Inc. 2929 7th Street, Suite 105 Berkeley, CA 94710 Tel: 510-982-6030See details»
Caribou Biosciences - Golden
Caribou Biosciences is headquartered in Berkeley, California and was founded in 2011 by to James Berger, Jennifer A. Doudna, Martin Jinek, and Rachel E. Haurwitz.The company uses …See details»
Caribou Biosciences Announces Expansion of Scientific Advisory …
Caribou Biosciences, Inc. 2929 7th Street, Suite 105 Berkeley, CA 94710 Tel: 510-982-6030See details»
Caribou Biosciences Appoints Sri Ryali as Chief …
BERKELEY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sri Ryali as …See details»
Caribou Biosciences Org Chart + Executive Team - The Official Board
For each of our 1,297,824 listed executives, discover their exact roles and their biographies.See details»
Who Owns Caribou Biosciences – CanvasBusinessModel.com
Oct 2, 2024 Website: https://www.cariboubio.com; Focus: CRISPR technologies and allogenic cell therapies for oncology; With a team of world-class scientists and researchers, Caribou …See details»
Leadership | Board of Directors | SAB | Caribou Biosciences
She serves on the board of directors of Seer, Inc. and the Biotechnology Innovation Organization (BIO). Rachel earned an AB in biological sciences from Harvard College and a PhD in …See details»
Caribou Biosciences (USA) Funding: $317.7M - Medical Startups
Apr 24, 2025 Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing. Our proprietary technology puts us at the forefront of the development of new medical …See details»
Caribou Biosciences Reports First Quarter 2025 Financial ... - Nasdaq
May 8, 2025 --Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter 2025 and …See details»
Caribou Biosciences (CRBU) Company Profile & Description
Jul 23, 2021 Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic …See details»
Caribou Biosciences | Leukemia and Lymphoma Society
Sep 3, 2024 For more information about Caribou, visit www.cariboubio.com. Recent News. September 3, 2024 - announced the FDA granted Fast Track designations to CB-012 for …See details»
Stephen Smith - Associate Director - Caribou Biosciences - LinkedIn
At the Automobile Club of Southern California I managed a team of 14 employees, improved organization wide customer service procedures, and helped to develop a nationally distributed …See details»
Caribou Biosciences Reports First Quarter 2025 Financial Results …
May 8, 2025 Caribou is focused on CB-010 and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with …See details»
Allogeneic T cells and NK cells | chRDNAs | Caribou Biosciences
Encore: A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) for relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 …See details»
Leadership | Board of Directors | SAB | Caribou Biosciences
In 2018, the Association for Women in Science recognized Rachel with the annual Next Generation Award. She serves on the board of directors for Biotechnology Innovation …See details»
U.S. tribes bolster caribou recovery and restoration in British …
1 day ago NAKUSP, British Columbia – Six years after the last wild caribou in the Lower 48 was relocated to Canada, conservationists and Inland Northwest tribes see a glimmer of hope less …See details»
Caribou Biosciences Announces Strategic Pipeline Prioritization …
Apr 24, 2025 -- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 ---- Two robust clinical datasets …See details»
Caribou Biosciences Announces Co-Founding of Intellia Therapeutics
Nov 18, 2014 Caribou Biosciences, Inc. 2929 7th Street, Suite 105 Berkeley, CA 94710 Tel: 510-982-6030See details»